Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AdVEGF-All6A+ for diffuse coronary artery disease
NCT01757223Phase 2Withdrawn
- Sponsor
- Weill Cornell Medicine
- Start
- Dec 2020
- Primary completion
- Oct 2030
- Modality
- Gene Editing, Gene Silencing, Adenoviral Vectors
01
Overview
Phase 2, randomised, double-blind trial of encoberminogene rezmadenovec in coronary artery disease (CAD) (5 arms), sponsored by Weill Cornell Medicine. Primary endpoint: Time to 1 mm ST depression during exercise-stress testing at 6 months. Planned start Dec 2020; status: withdrawn.
02
Drugs
encoberminogene rezmadenovec
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT01757223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01757223.